Author
Thomas J. Bollyky
Other affiliations: Center for Global Development, Georgetown University
Bio: Thomas J. Bollyky is an academic researcher from Council on Foreign Relations. The author has contributed to research in topics: Global health & Tobacco control. The author has an hindex of 14, co-authored 42 publications receiving 935 citations. Previous affiliations of Thomas J. Bollyky include Center for Global Development & Georgetown University.
Papers
More filters
TL;DR: In this paper, the authors use the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to improve and expand the quantification of personal health-care access and quality for 195 countries and territories from 1990 to 2015.
427 citations
TL;DR: High levels of government and interpersonal trust, as well as less government corruption, were also associated with higher COVID-19 vaccine coverage among middle-income and high-income countries where vaccine availability was more widespread, and lower corruption was associated with greater reductions in mobility.
129 citations
TL;DR: It is project that the countries with the greatest increases in the share of disease burden attributable to noncommunicable disease over the next twenty-five years will also be the least prepared for the change, as they ranked low on the authors' capacity index and are expected to have the smallest increases in national health spending.
Abstract: Demographic and epidemiological changes are shifting the disease burden from communicable to noncommunicable diseases in lower-income countries. Within a generation, the share of disease burden attributed to noncommunicable diseases in some poor countries will exceed 80 percent, rivaling that of rich countries, but this burden is likely to affect much younger people in poorer countries. The health systems of lower-income countries are unprepared for this change. We examined the shift to noncommunicable diseases and estimated preparedness for the shift by ranking 172 nations using a health system capacity index for noncommunicable disease. We project that the countries with the greatest increases in the share of disease burden attributable to noncommunicable disease over the next twenty-five years will also be the least prepared for the change, as they ranked low on our capacity index and are expected to have the smallest increases in national health spending. National governments and donors must invest mo...
126 citations
TL;DR: When enforced by free and fair elections, democracies are more likely than autocracies to lead to health gains for causes of mortality that have not been heavily targeted by foreign aid and require health-care delivery infrastructure.
107 citations
TL;DR: In this paper, a proposal for global cooperation to ensure equitable distribution of vaccines and therapies for coronavirus disease 2019 (COVID-19) is presented. But the proposal does not consider the distribution of medical products both within and among countries.
Abstract: Scientists from across the globe are racing to develop effective vaccines and therapeutics for coronavirus disease 2019 (COVID-19). Plans are beginning to emerge for ensuring the equitable worldwide distribution of vaccines and therapeutics resulting from biomedical innovations. Absent broad agreement and buy-in on those plans, governments may prioritize their own populations, resulting in inequitable distribution of medical products both within and among countries. During the 2009 influenza A(H1N1) pandemic, wealthy nations bought virtually all vaccine supplies. Even after the WHO appealed for donations, supplies for low- and middle-income countries (LMICs) were limited. The White House may have already sought exclusive access to a COVID-19 vaccine candidate. European and Asian countries have imposed export controls on personal protective equipment and ventilators, with similar export controls likely to extend to COVID-19 vaccine and therapeutic stocks.
The development and widespread distribution of COVID-19 medical treatments are a common global interest. Here we offer a proposal for global cooperation to ensure equitable distribution of vaccines and therapies for COViD-19.
87 citations
Cited by
More filters
Theo Vos1, Amanuel Alemu Abajobir, Kalkidan Hassen Abate2, Cristiana Abbafati3 +775 more•Institutions (305)
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016.
10,401 citations
Mohsen Naghavi1, Amanuel Alemu Abajobir2, Cristiana Abbafati3, Kaja Abbas4 +598 more•Institutions (31)
TL;DR: The Global Burden of Disease 2016 Study (GBD 2016) provides a comprehensive assessment of cause-specific mortality for 264 causes in 195 locations from 1980 to 2016 as discussed by the authors, which includes evaluation of the expected epidemiological transition with changes in development and where local patterns deviate from these trends.
3,228 citations
Simon I. Hay, Amanuel Alemu Abajobir1, Kalkidan Hassen Abate2, Cristiana Abbafati3 +800 more•Institutions (32)
TL;DR: At a global level, DALYs and HALE continue to show improvements and the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning.
3,029 citations
University of Pittsburgh1, Institute for Health Metrics and Evaluation2, University of Washington3, University of British Columbia4, The George Institute for Global Health5, Federal University of São Paulo6, Charité7, University of London8, Seattle Children's9, University of São Paulo10, University of Melbourne11
TL;DR: Despite declining age-standardised incidence and mortality, sepsis remains a major cause of health loss worldwide and has an especially high health-related burden in sub-Saharan Africa.
2,419 citations